Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,901–4,000 of 15,747
Age-Stratified COVID-19 Spread Analysis and Vaccination: A Multitype Random Network Approach
Chen, X., Zhu, G., Zhang, L., Fang, Y. M., Guo, L., & Chen, X. (2021) · IEEE Transactions on Network Science and Engineering · doi:10.1109/tnse.2021.3075222 · Cited by 26
mRNA Vaccine Nanoplatforms and Innate Immunity
Wei, L., Dong, C., Zhu, W., & Wang, B. (2024) · Viruses · doi:10.3390/v16010120 · Cited by 31
Ferrari, D., Resta, C. D., Tomaiuolo, R., Sabetta, E., Pontillo, M., Motta, A., & Locatelli, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.020 · Cited by 26
“Unlike conventional vaccines, Comirnaty is a lipid nanoparticle-formulated, nucleoside-modified RNA (modRNA) encoding the SARS-CoV-2 full-length spike-protein (S-protein) [1], locked in the pre-fusion conformation [3].”
Özdede, A., Güner, S., Ozcifci, G., Yurttaş, B., Dincer, Z. T., Atlı, Z., Uygunoğlu, U., Durmaz, E., Uçar, D., Uğurlu, S., et al. (2022) · Rheumatology International · doi:10.1007/s00296-022-05119-y · Cited by 31
Berger, M., Toussaint, F., Djemaa, S. B., Maquoi, E., Pendeville, H., Évrard, B., Jérôme, C., Chain, J. L., Lechanteur, A., Mottet, D., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302712 · Cited by 38
Volkmann, A., Koopman, G., Mooij, P., Verschoor, E. J., Verstrepen, B. E., Bogers, W. M. J. M., Idorn, M., Paludan, S. R., Vang, S., Nielsen, M. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857440 · Cited by 28
“Since ABNCoV2 induced comparable neutralizing antibodies and protection in the rhesus macaque model as licensed vaccines in the same model, it is tempting to speculate that ABNCoV2 may also be efficacious against SARSCoV-2 in humans, in which the licensed vaccines have demonstrated protection against symptomatic COVID…”
BackgroundNucleic acid functionalized extracellular vesicles as promising therapeutic systems for nanomedicine
Liu, C., He, D., Cen, H., Chen, H., Li, L., Nie, G., Zhong, Z., He, Q., Yang, X., Guo, S., et al. (2022) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2021.21 · Cited by 39
T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles
Hensen, L., Illing, P. T., Rowntree, L. C., Davies, J., Miller, A., Tong, S. Y. C., Habel, J. R., van de Sandt, C. E., Flanagan, K. L., Purcell, A. W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812393 · Cited by 30
Advances in biomaterials for the treatment of retinoblastoma
Farhat, W., Yeung, V., Ross, A., Kahale, F., Boychev, N., Kuang, L., Chen, L., & Ciolino, J. B. (2022) · Biomaterials Science · doi:10.1039/d2bm01005d · Cited by 29
Zhou, R., Liu, N., Li, X., Peng, Q., Yiu, C.-K., Huang, H., Yang, D., Du, Z., Kwok, H.-Y., Au, K.-K., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100660 · Cited by 26
Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy
Kaplan, B. M., Farzan, S., Coscia, G. T., Rosenthal, D. W., McInerney, A., Jongco, A. M., Ponda, P., & Bonagura, V. R. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.10.019 · Cited by 26
Engineering challenges and translational opportunities in emerging gene delivery platforms
Ma, Y., Dong, S., Wu, A., Jeong, S. D., Lee, A. S., Jiang, W., & Kim, B. Y. S. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01643-5 · Cited by 49
Chansaenroj, J., Suntronwong, N., Kanokudom, S., Assawakosri, S., Yorsaeng, R., Vichaiwattana, P., Klinfueng, S., Wongsrisang, L., Srimuan, D., Thatsanatorn, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10071071 · Cited by 27
“139 One dose contains 30 and 100 μg for BNT162b2 and mRNA-1273, respectively [24,25].”
BackgroundZhang, B., Zhang, Z., Koeken, V. A. C. M., Kumar, S., Aillaud, M., Tsay, H.-C., Liu, Z., Kraft, A. R. M., Soon, C. F., Odak, I., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100232 · Cited by 28
“Although vaccines reduce the risk of major illness and mortality, the molecular mechanisms underlying the heterogeneous outcome in disease presentation remain unclear.(3) A number of studies have examined the complex interplay between peripheral blood leukocytes in COVID-19 and linked immune activation and specific ce…”
What Happens to the Immune System after Vaccination or Recovery from COVID-19?
Tiyo, B. T., Schmitz, G. J. H., Ortega, M. M., da Silva, L. T., de Almeida, A., Oshiro, T. M., & Duarte, A. J. D. S. (2021) · Life · doi:10.3390/life11111152 · Cited by 31
Li, L., Müftüoğlu, M., Liang, S., Basyal, M., Lv, J., Akdogan, M. E., Chen, K., Andreeff, M., Flowers, C. R., & Parmar, S. (2022) · JCI Insight · doi:10.1172/jci.insight.156559 · Cited by 28
“A growing body of evidence revealed that COVID-19 vaccines are highly efficacious in preventing COVID-19 infections(2).”
BackgroundLeonard, R. A., Burke, K. N., Spreng, R. L., Macintyre, A. N., Tam, Y. K., Alameh, M., Weissman, D., & Heaton, N. S. (2024) · Nature Communications · doi:10.1038/s41467-024-52940-z · Cited by 29
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity
Blasi, F., Gramegna, A., Sotgiu, G., Saderi, L., Voza, A., Aliberti, S., & Amati, F. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106355 · Cited by 27
Holroyd, K., Healy, B., Conway, S. E., Houtchens, M., Bakshi, R., Bhattacharyya, S., Bose, G., Galetta, K. M., Kaplan, T., Severson, C., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104079 · Cited by 22
A case for investment in clinical metagenomics in low-income and middle-income countries
Marais, G. J. K., Hardie, D. R., & Brink, A. J. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00328-7 · Cited by 29
Dynamic allostery highlights the evolutionary differences between the CoV-1 and CoV-2 main proteases
Campitelli, P., Lu, J., & Ozkan, S. B. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.03.012 · Cited by 22
“The DFI value of position i is then treated as the displacement response of position i relative to the net displacement response of the entire protein, which is calculated by sequentially perturbing each position in the structure (3).”
Kissling, E., Hooiveld, M., Martínez‐Baz, I., Mazagatos, C., William, N., Vilcu, A., Kooijman, M. N., Ilić, M., Domegan, L. M., Machado, A., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.21.2101104 · Cited by 26
Sars-CoV2 vaccine hesitancy in Italy: A survey on subjects with diabetes
Scoccimarro, D., Panichi, L., Ragghianti, B., Silverii, G. A., Mannucci, E., & Monami, M. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.002 · Cited by 25
Kim, S. Y. (2022) · Life Cycle · doi:10.54724/lc.2022.e2 · Cited by 29
Association Between Vaccination Status and Outcomes in Patients Admitted to the ICU With COVID-19*
van Diepen, S., McAlister, F. A., Chu, L. M., Youngson, E. R. E., Kaul, P., & Kadri, S. S. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005928 · Cited by 28
Xing, R. S., Song, X., Liu, L., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122277 · Cited by 25
Heidari, S., Durrheim, D., Faden, R., Kochhar, S., MacDonald, N., Olayinka, F., & Goodman, T. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2021-006854 · Cited by 23
“35 36 In the context of vaccine shortages, sex-and gender-based analysis of efficacy and adverse event profiles, or consideration of alternative dosage, frequency of administration or timing interval, could provide useful insights, suggest ways to enhance efficacy, reduce adverse reactions and…”
BackgroundPonce‐de‐León, S., Torres, M., Soto-Ramírez, L. E., Calva, J. J., Santillán‐Doherty, P., Carranza-Salazar, D. E., Carreño, J. M., Carranza, C., Juárez, E., Carreto-Binaghi, L. E., et al. (2022) · medRxiv · doi:10.1101/2022.02.08.22270676 · Cited by 25
Bhurwal, A., Mutneja, H. R., Bansal, V., Goel, A., Arora, S. K., Attar, B. M., Minacapelli, C. D., Kochhar, G. S., Chen, L. A., Brant, S. R., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16913 · Cited by 27
Paramithiotis, E., Sugden, S., Papp, E., Bonhomme, M., Chermak, T., Crawford, S. Y., Demetriades, S. Z., Galdos, G., Lambert, B. L., Mattison, J. E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880784 · Cited by 28
Walker, D. M., Swoboda, C. M., Shiu‐Yee, K., Tarver, W. L., Nolan, T. S., & Joseph, J. J. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07780-2 · Cited by 27
Gronbeck, C., & Grant-Kels, J. M. (2021) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2021.05.027 · Cited by 27
Adaptive and optimized COVID-19 vaccination strategies across geographical regions and age groups
Molla, J., Chávez, A. P. D. L., Hiraoka, T., Ala-Nissilä, T., Kivelä, M., & Leskelä, L. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009974 · Cited by 28
Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
Akiyama, H., Kakiuchi, S., Rikitake, J., et al. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01245 · Cited by 25
“In particular, messenger ribonucleic acid (mRNA) vaccines such as Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273 have shown very positive results in clinical trials and are already being administered in many countries around the world [2,3].”
Safety of COVID-19 Vaccines: Spotlight on Neurological Complications
Tondo, G., Virgilio, E., Naldi, A., Bianchi, A., & Comi, C. (2022) · Life · doi:10.3390/life12091338 · Cited by 29
Tylicki, L., Biedunkiewicz, B., Dąbrowska, M., et al. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16069 · Cited by 25
Altomare, C. G., Adelsberg, D. C., Carreño, J. M., Sapse, I. A., Amanat, F., Ellebedy, A. H., Simon, V. R., Krammer, F., & Bajic, G. (2022) · mBio · doi:10.1128/mbio.03580-21 · Cited by 24
“glycoprotein but that mRNA vaccination, in contrast, induces consistently high titers (1, 2, 30).”
BackgroundReckless spreader or blameless victim? How vaccination status affects responses to COVID-19 patients
Claudy, M., Vijayakumar, S., & Campbell, N. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.115089 · Cited by 24
“COVID-19 vaccinations significantly reduce transmissibility as well as hospitalizations and mortality rates from COVID-19 (e.g., Haas et al., 2021; Polack et al., 2020).”
Joshi, G., Borah, P., Thakur, S., Sharma, P., Mayank, M., & Ramarao, P. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1995283 · Cited by 32
“In a placebo-controlled, randomized, phase 2/3 trial (NCT04368728), BNT162b2 was found to be ~95% effective among individuals with a history of no previous or existing infection.(58) As evident from the large trials, excellent results of BNT162b2 (brand name: Comirnaty) led to the granting of EUA in the UK.”
MethodResultImmunity and infectivity in covid-19
Johnston, C., Hughes, H. C., Lingard, S., Hailey, S., & Healy, B. (2022) · BMJ · doi:10.1136/bmj-2020-061402 · Cited by 25
Cheung, K. S., Lam, L.-K., Zhang, R., Ooi, P. H., Tan, J. T., To, E. W.-P., Hui, C.-H., Chan, K., Seto, W., Hung, I. F., et al. (2022) · Vaccines · doi:10.3390/vaccines10071122 · Cited by 27
“The overall efficacy (protection from symptomatic COVID-19) after two doses of BNT162B2 is 95% [3], while that of CoronaVac is 70% [4].”
BackgroundAl‐Sadeq, D. W., Shurrab, F. M., Ismail, A., Amanullah, F. H., Thomas, S., Al-Dewik, N. I. E., Yassine, H. M., Rahim, H. F. A., Abu-Raddad, L. J., & Nasrallah, G. K. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab190 · Cited by 23
“They showed an efficacy rate of more than 94% [3, 4] and 158 were reported to be safe.”
BackgroundSelf-citationLenart, K., Cerveira, R. A., Hellgren, F., Ols, S., Sheward, D. J., Kim, C., Cagigi, A., Gagné, M., Davis, B. J., Germosen, D., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00806-2 · Cited by 28
Hurdles to healing: Overcoming cellular barriers for viral and nonviral gene therapy
Honrath, S., Burger, M., & Leroux, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125470 · Cited by 31
Uaprasert, N., Pitakkitnukun, P., Tangcheewinsirikul, N., Chiasakul, T., & Rojnuckarin, P. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00776-5 · Cited by 27
Wang, K., Wong, E. L., Cheung, A. W.-L., Chung, V. C., Wong, C. H.-L., Dong, D., Wong, S. Y. S., & Yeoh, E. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04586-6 · Cited by 32
“1 3 vaccine (approximately 90% efficacy) [37] for children aged 12–17 years, and with parents who received the vaccine and received information on the effectiveness of the vaccine in both disease incidence and mortality in loss-framing messages, when other attributes were considered at their optimal levels.”
BackgroundMethodCOVID-19 vaccine strategies for Aotearoa New Zealand: a mathematical modelling study
Nguyen, T., Adnan, M., Nguyen, B. P., de Ligt, J., Geoghegan, J. L., Dean, R. A., Jefferies, S., Baker, M. G., Seah, W. K. G., Sporle, A. A., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100256 · Cited by 29
“[6] Polack FP , Thomas SJ , Kitchin N , Absalon J , Gurtman A , Lockhart S , et al.”
Hernández‐Bernal, F., Ricardo-Cobas, M. C., Martín‐Bauta, Y., Rodríguez-Martínez, E., Urrutia-Pérez, K., Urrutia-Pérez, K., Quintana-Guerra, J., Rodríguez, Z. N., Piñera-Martínez, M., Rodríguez‐Reinoso, J. L., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100497 · Cited by 40
Macciò, A., Oppi, S., & Madeddu, C. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00772-6 · Cited by 35
Yahav, D., Rozen‐Zvi, B., Mashraki, T., Atamna, A., Ben‐Zvi, H., Bar‐Haim, E., & Rahamimov, R. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-055611 · Cited by 29
Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins
Devi, Y. D., Goswami, H. B., Konwar, S., Doley, C., Dolley, A., Devi, A., Chongtham, C., Dowerah, D., Biswa, V., Jamir, L., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258645 · Cited by 28
“Sl No Type of protein Predicted B cell epitope Predicted T cell epitope Reference 1 Spike protein (S) Yes Yes [20] 4 structural proteins and 5 non-structural proteins (open reading frame (ORF)3a, ORF6, ORF7a, ORF8, ORF10); and 1 non-structural polyprotein (ORF1ab) Yes 2 S Yes Yes [21] 3 S Yes Yes [22] 4 N Yes Yes [23]…”
MethodLv, J., & Xiong, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179147 · Cited by 34
“However, they can also cause side effects, ranging from mild reactogenicity to rare, severe conditions [148].”
BackgroundSARS-CoV-2, COVID-19, and Reproduction: Effects on Fertility, Pregnancy, and Neonatal Life
Harb, J., Debs, N., Rima, M., Wu, Y., Cao, Z., Kovacic, H., Fajloun, Z., & Sabatier, J. (2022) · Biomedicines · doi:10.3390/biomedicines10081775 · Cited by 30
“Even though COVID-19 vaccination has been shown to be more or less effective in up to 90% of cases, only about three-quarters of non-pregnant women agreed to get vaccinated, compared to around 50% of pregnant women [93].”
ResultForster, M., Wuerstlein, R., Koenig, A., Amann, N., Beyer, S., Kaltofen, T., Degenhardt, T., Burges, A., Trillsch, F., Mahner, S., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.10.012 · Cited by 25
“administration during standard of care for cancer patients has been described by the recommendations of major oncologic societies [8], past and ongoing vaccine safety and efficacy clinical trials have excluded patients undergoing anticancer treatment [9,10].”
BackgroundTut, G., Lancaster, T., Sylla, P., Butler, M., Kaur, N., Spalkova, E., Bentley, C., Amin, U., Jadir, A., Hulme, S., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00118-0 · Cited by 21
“2,3 To date, there is poor understanding of the relative immuno genicity of these two regimens in LTCF residents.”
Karim, F., Riou, C., Bernstein, M. P., Jule, Z., Lustig, G., van Graan, S., Keeton, R., Upton, J., Ganga, Y., Khan, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46673-2 · Cited by 31
Advancing mRNA technologies for therapies and vaccines: An African context
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25
Castellanos, M. M., Gressard, H., Li, X., Magagnoli, C., Moriconi, A., Stranges, D., Strodiot, L., Soto, M., Zwierzyna, M., & Campa, C. (2023) · Vaccines · doi:10.3390/vaccines11071153 · Cited by 30
“Particularly, mRNA-based vaccines have emerged as a novel modality to develop products at an accelerated pace, a key benefit during a pandemic situation [28].”
BackgroundSathian, B., Asim, M., Banerjee, I., Roy, B., Pizarro, A. B., Mancha, M. A., van Teijlingen, E., Kord‐Varkaneh, H., Mekkodathil, A. A., Subramanya, S. H., et al. (2021) · Nepal Journal of Epidemiology · doi:10.3126/nje.v11i1.36163 · Cited by 27
Ahamad, M. M., Aktar, S., Uddin, M. J., Rashed-Al-Mahfuz, M., Azad, A., Uddin, S., Alyami, S. A., Sarker, I. H., Lió, P., Quinn, J. M. W., et al. (2021) · medRxiv · doi:10.1101/2021.04.16.21255618 · Cited by 25
“There have been a small number of fatalities post COVID-19 vaccination [15,16,22], although the degree to which they are linked to the vaccination itself is unclear and still under active investigation [23,24].”
BackgroundSelf-citationMeasuring and Promoting SARS-CoV-2 Vaccine Equity: Development of a COVID-19 Vaccine Equity Index
Pressman, A. R., Lockhart, S. H., Shen, Z., & Azar, K. M. J. (2021) · Health Equity · doi:10.1089/heq.2021.0047 · Cited by 23
Self-citationChu, K., Kang, H.-J., Yoon, K.-W., Lee, H., Moon, E., Han, B. K., & Quan, F. (2021) · Vaccines · doi:10.3390/vaccines9080920 · Cited by 27
“Although several vaccines have been approved for emergency use by the United States Food and Drug Administration (FDA) [8], continued efforts to improve vaccine efficacy and safety are needed as indicated by newly emerging SARS-CoV-2 variants [9].”
BackgroundBacterium-like particles derived from probiotics: progress, challenges and prospects
Zhou, X., Gao, M., De, X., Sun, T., Bai, Z., Luo, J., Wang, F., & Ge, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1263586 · Cited by 30
van den Hoogen, L. L., Boer, M. C., Postema, A., de Rond, L., de Zeeuw‐Brouwer, M., Pronk, I., Wijmenga‐Monsuur, A. J., Bijvank, E., Kruiper, C., Beckers, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10091480 · Cited by 28
“Early studies of BNT162b2 demonstrated high vaccine efficacy against COVID-19 infection, after completing the full vaccination schedule [2].”
BackgroundCOVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2
Kumar, N., Quadri, S., AlAwadhi, A. I., & AlQahtani, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812606 · Cited by 24
Skroza, N., Bernardini, N., Tolino, E., Proietti, I., Mambrin, A., Marchesiello, A., Marraffa, F., Rossi, G., Volpe, S., & Potenza, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153355 · Cited by 25
“Introduction Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy in course, to date, the effects of these vaccines in such patients have yet to be clearly defined [1,2].”
BackgroundDevelopment of COVID-19 vaccines utilizing gene therapy technology
Nakagami, H. (2021) · International Immunology · doi:10.1093/intimm/dxab013 · Cited by 25
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
Kandimalla, R. J. L., Chakraborty, P., Vallamkondu, J., Chaudhary, A., Samanta, S., Reddy, P. H., Feo, V. D., & Dewanjee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9111740 · Cited by 28
“In a clinical trial consisting of 43,448 volunteers (≥16 years), BNT162b2 was given in two doses (30 μg each) 21 days apart [104].”
BackgroundMethodMurdoch, L., Quan, K., Baber, J., Ho, A. W. Y., Zhang, Y., Xu, X., Lu, C., Cooper, D., Koury, K. J., Lockhart, S. P., et al. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00863-5 · Cited by 24
Self-citationBreakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Mazuecos, A., Villanego, F., Zárraga, S., López, V., Oppenheimer, F., Llinàs-Mallol, L., Hernández, A. M. G., Rivas, A., Ruiz-Fuentes, M. C., Toapanta, N., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004119 · Cited by 30
“1%, respectively, in their clinical trials, defined as preventing the first occurrence of symptomatic coronavirus disease 2019 (COVID19).(2,3) Furthermore, COVID-19 mRNA vaccines have demonstrated to be highly effective against SARS-CoV-2 infection requiring hospitalization or intensive care unit (ICU) admission in th…”
BackgroundResultA comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines
Abdolmaleki, G., Taheri, M. A., Paridehpour, S., Mohammadi, N. M., Tabatabaei, Y. A., Mousavi, T., & Amin, M. (2022) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-022-00446-8 · Cited by 30
Salod, Z., & Mahomed, O. H. (2022) · Vaccines · doi:10.3390/vaccines10111785 · Cited by 30
de Sousa, I. P., Wallace, Z. S., Cavalcante, S. C., Ribeiro, M. P. F., Silva, J. A. B. M., Cavalcante, R. C. M., Scheuermann, R. H., & Palatnik, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-21207-2 · Cited by 29
Zamani, P., Mashreghi, M., Bazaz, M. R., Zargari, S., Alizadeh, F. L., Dorrigiv, M., Abdoli, A., Aminianfar, H., Hatamipour, M., Zarqi, J., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.025 · Cited by 26
Kertes, J., Gez, S. B., Saciuk, Y., Supino‐Rosin, L., Shamir-Stein, N., Mizrahi-Reuveni, M., & Zohar, A. E. (2021) · Emerging infectious diseases · doi:10.3201/eid2802.211834 · Cited by 32
Using big data to understand the online ecology of COVID-19 vaccination hesitancy
Teng, S., Jiang, N., & Khong, K. W. (2022) · Humanities and Social Sciences Communications · doi:10.1057/s41599-022-01185-6 · Cited by 31
Potential COVID‐19 Therapeutic Agents and Vaccines: An Evidence‐Based Review
Khani, E., Khiali, S., & Entezari‐Maleki, T. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1822 · Cited by 28
Sabu, J. M., Zahid, I., Jacob, N., Alele, F. O., & Malau‐Aduli, B. S. (2022) · Vaccines · doi:10.3390/vaccines10111880 · Cited by 24
“The incidence of serious adverse effects has also been reported as low in adults, just as indicated for children and adolescents in this study’s findings [57,58].”
BackgroundActive Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan
Abdel‐Qader, D. H., Abdel-Qader, H., Silverthorne, J., Kongkaew, C., Meslamani, A. Z. A., Hayajneh, W. A., Ata, O. A., Shnaigat, W., Aburuz, S., Nsour, M. A., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01191-1 · Cited by 25
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A., Grunenberg, N. A., Allen, M., Antony, J., Asante, K. P., Bhate, A. S., Beresnev, T. H., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00263-1 · Cited by 44
Fisher, C. R., Medie, F. M., Luu, R. J., Gaibler, R. B., Mulhern, T. J., Miller, C. R., Zhang, C. J., Rubio, L. D., Marr, E. E., Vijayakumar, V., et al. (2023) · Cells · doi:10.3390/cells12222639 · Cited by 28
Hanney, S. R., Straus, S. E., & Holmes, B. J. (2022) · Health Research Policy and Systems · doi:10.1186/s12961-022-00883-6 · Cited by 34
“Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China.”
BackgroundInfluentialArtificial intelligence-guided design of lipid nanoparticles for mRNA delivery
Su, K., Qiu, J., Xu, T., & Liu, S. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.029 · Cited by 48
“High-throughput screening (HTS) and ML prediction resulted in the discovery of novel ionizable lipid 119-23 with excellent performance from a large chemical library, whose mRNA delivery efficiency outperformed existing commercially available lipids ( e.g. , DLin-MC3-DMA (MC3) and SM-102).”
DrugWAS: Drug‐wide Association Studies for COVID‐19 Drug Repurposing
Bejan, C. A., Cahill, K. N., Staso, P. J., Choi, L., Peterson, J. F., & Phillips, E. J. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2376 · Cited by 26
Akuka, P. N. A., Seidu, B., & Bornaa, C. S. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/7493087 · Cited by 24
“82 [7] η2 ≥ η1 Efficacy of second dose of vaccine 0.”
Mhawish, H., Mady, A., Alaklobi, F. A., Aletreby, W., Asad, T., Alodat, M., Alharthy, A., Abdulrahman, B., Almahwi, S., & Memish, Z. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102951 · Cited by 22
“Accordingly, an against-the-clock endeavor began to create such a vaccine, that ultimately resulted in the authorization of several vaccines in Europe and the United States, based on phase 2/3 safety and efficacy randomized clinical trials (RCT), reporting high efficacy [4 – 6].”
Litaker, J. R., Tamez, N., Bray, C. L., Durkalski, W., & Taylor, R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010368 · Cited by 25
“Two of these vaccines were developed using novel mRNA technology which, despite having been used successfully in animals and having a strong safety profile [29,30], had not been used in humans until Emergency Use Authorization was granted.”
BackgroundCOVID-19 Vaccines in Older Adults
Liang, C., Lee, W., Peng, L., Meng, L., Hsiao, F., & Chen, L. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.03.006 · Cited by 28
“2% of the Pfizer/BioNTech vaccine trial participants were aged 55 years old and older, less than 5% of individuals were older than 75 years.(67) Approximately one-quarter of Moderna vaccine trial participants were aged 65 years and older,(14) but the Oxford-AstraZeneca vaccine trial enrolled only 5% participants aged…”
BackgroundKaur, U., Bala, S., Joshi, A. U., Reddy, N. T. S., Japur, C., Chauhan, M., Pedapanga, N., Kumar, S., Mukherjee, A., Mishra, V. K., et al. (2022) · Vaccines · doi:10.3390/vaccines10071153 · Cited by 26
COVID-19 Vaccination for Persons with Parkinson’s Disease: Light at the End of the Tunnel?
Bloem, B. R., Trenkwalder, C., Sánchez‐Ferro, Á., Kalia, L. V., Alcalay, R. N., Chiang, H., Kang, U. J., Goetz, C. G., Brundin, P., & Papa, S. M. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212573 · Cited by 28
Saied, A. A., Metwally, A. A., Alobo, M., Shah, J., Sharun, K., & Dhama, K. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106233 · Cited by 29
Marsili, L., Bo, M. D., Berti, F., & Toffoli, G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101654 · Cited by 28
Baars, A. E., Kuitwaard, K., de Koning, L. C., Luijten, L. W. G., Kok, W. M., Eftimov, F., Wieske, L., Goedee, H. S., van der Pol, W. L., Blomkwist‐Markens, P. H., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201376 · Cited by 33
Development and application of ribonucleic acid therapy strategies against COVID-19
Lin, N., Liu, M., Gou, Y., Yang, Y., He, B., & Huang, J. H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72706 · Cited by 27
“In 2021, faced with the growing threat from the COVID-19 pandemic, FDA approved two mRNA vaccines developed respectively by the companies of Pfizer/BioNtech and Moderna [26, 27].”
BackgroundDiscovery of All- d -Peptide Inhibitors of SARS-CoV-2 3C-like Protease
Eberle, R. J., Sevenich, M. M., Gering, I., Scharbert, L., Strodel, B., Lakomek, N., Santur, K., Mohrlüder, J., Coronado, M. A., & Willbold, D. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00735 · Cited by 25
Dombrádi, V., Joó, T., Palla, G., Pollner, P., & Belicza, É. (2021) · BMC Public Health · doi:10.1186/s12889-021-12386-0 · Cited by 30
Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 35
“19,110 This success has sparked renewed interest and optimism in the potential of mRNA vaccines to tackle other infectious diseases.”
InfluentialGe, X., He, Z., Yang, H., Pan, X., Yan, L., Shi, Y., Chen, Y., & Liu, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113906 · Cited by 29
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.